SABCS Conference Coverage

What’s New In Breast Cancer Research? SABCS20 Goes Virtual

(Fred Hutch) Dec 18, 2020 - Hutch scientists share findings on treatment, imaging, CAR T therapy, COVID-19’s impact on cancer patients and more.

read article

Breast Cancer Index™ Demonstrates Its Ability To Predict Preferential Endocrine Benefit Irrespective Of Risk For HR+ Early-Stage Breast Cancer Patients

(Morningstar) Dec 17, 2020 - Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage breast cancer patients was highlighted during a Spotlight session on December 9th at this years’ San Antonio Breast Cancer Symposium.

read article

Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS

(Puma) Dec 11, 2020 - Puma Biotechnology, Inc., a biopharmaceutical company, presented efficacy and safety outcomes in a subgroup of patients from the NALA trial who had central nervous system (CNS) metastases at baseline, with a particular focus on CNS-specific endpoints, at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation, entitled “Impact of neratinib plus capecitabine on outcomes in HER2-positive metastatic breast cancer patients with central nervous system disease at baseline: Findings from the phase 3 NALA trial,” is being presented at a Spotlight Poster Discussion Session by Cristina Saura, M.D., Ph.D., Head of Breast Cancer Unit, Vall d’Hebrón University Hospital, an investigator of the trial. A copy of this poster presentation is available on the Puma website.

read corporate press release

AKT Inhibitor Disappoints in Tough-to-Treat Breast Cancer

(MedPage Today) Dec 13, 2020 - Adding the investigational agent ipatasertib to paclitaxel failed to improve progression-free survival (PFS) in patients with PIK3CA/AKT1/PTEN-altered advanced triple-negative breast cancer, a researcher reported.

read article (free registration required)

Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer

(Gilead) Dec 10, 2020 - Gilead Sciences, Inc. is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San Antonio Breast Cancer Symposium being held virtually December 8-11, 2020. The new data and analyses from the ASCENT trial continue to demonstrate the high clinical activity of Trodelvy in this patient population with traditionally poor outcomes.

read corporate press release

PENELOPE-B: Palbociclib Disappoints in HR+, HER2– Breast Cancer

(Medscape Medical News) Dec 10, 2020 - The CDK4/6 inhibitor palbociclib provides no significant benefit in patients with hormone receptor–positive (HR+), HER2-negative primary breast cancer, according to first results from the PENELOPE-B trial. In this phase 3 trial, adding palbociclib to standard endocrine therapy did not improve invasive disease-free survival (iDFS) in patients who were at high risk of relapse following neoadjuvant chemotherapy (NACT).

read article (free registration required)

SABCS 2020: Novel Oral Taxane Demonstrates Efficacy in CONTESSA Trial

(OBR) Dec 11, 2020 - An all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival (PFS) and other endpoints, compared with capecitabine alone, in patients with HER2-negative, hormone receptor (HR)-positive metastatic breast cancer (MBC), according to findings from the CONTESSA trial. These results, from the phase 3 CONTESSA trial, were presented at the 2020 San Antonio Breast Cancer Symposium (Abstract GS4-01). In the trial, patients had previously received no more than one chemotherapy regimen for advanced disease and a taxane in the neoadjuvant or adjuvant setting.

read article

SABCS 2020: Pembrolizumab Plus Chemo Continues to Shine in New KEYNOTE-355 Analysis

(OBR) Dec 11, 2020 - Pembrolizumab plus chemotherapy improved the progression-free survival, overall response rate, durable complete remission, and duration of response for patients with locally recurrent, unresectable or metastatic triple negative breast cancer (TNBC) with tumors expressing PD-L1 and a combined positive score (CPS) of 10 or more, according to new findings from the KEYNOTE-355 trial. The additional endpoint results, which were reported at the 2020 San Antonio Breast Cancer Symposium, follow a previously reported progression-free survival (PFS) benefit for the pembrolizumab and chemotherapy combination during an interim analysis.

read article

SABCS 2020: Salvage Chemo Appears Ineffective For High Risk, ER-Positive, HER2-Negative Breast Cancer

(OBR) Dec 11, 2020 - In patients with estrogen receptor (ER)-positive, HER2-negative breast cancer that is resistant to neoadjuvant endocrine therapy, the use of salvage neoadjuvant chemotherapy is not likely to induce a complete or near complete response, according to findings presented at the 2020 San Antonio Breast Cancer Symposium. The results come from the phase 3 ALTERNATE trial, which examines the use of anastrozole, fulvestrant, or both in postmenopausal women with clinical stage II and III ER-positive, HER2-negative breast cancer that is resistant to endocrine therapy.

read article

Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)

(Odonate) Dec 11, 2020 - CONTESSA achieved primary endpoint – tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival (PFS) versus the approved dose of capecitabine alone (hazard ratio=0.716; p=0.003).

read corporate press release

Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint for Clinical Low Risk Breast Cancer Patients at SABCS 2020

(Agendia) Dec 11, 2020 - Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted in an oral presentation by Laura van’t Veer, Ph.D., Co-founder and Chief Research Officer, at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020).

read corporate press release

New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice

(Exact Sciences) Dec 11, 2020 - Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions in breast cancer patients with high clinical risk, including those with node-positive disease.

read corporate press release

Educational Session Explores Advances In Treating ER Positive Breast Cancer

(SABCS 2020) Dec 11, 2020 - One of the enduring problems in treating ER+ breast cancer is its persistent tendency to recur. HER+ and triple negative breast cancers usually recur within the first few years after treatment, but ER+ cancers have a steady rate of relapse over decades.

read article

Good Clinical Outcomes Only A Part Of Breast Cancer Recovery

(SABCS 2020) Dec 11, 2020 - Recovering from breast cancer means more than good clinical outcomes. The overarching goal is good quality of life, which means balancing clinical outcomes with treatment toxicities while preserving a positive body image, good sexual health and, for patients who want it, the opportunity for biological children.

read article

Mini-Symposium Explores Multiple Approaches To Breast Cancer Prevention

(SABCS 2020) Dec 11, 2020 - Just as no single breast cancer treatment is appropriate for all patients, no single prevention strategy is appropriate for all. Prophylactic mastectomy is highly effective in preventing breast cancer but is not often acceptable.

read article

ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive Metastatic Breast Cancer

(AstraZeneca) Dec 10, 2020 - Updated results from the positive DESTINY-Breast01 Phase II trial showed AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) continued to demonstrate impressive efficacy and durable responses in patients with HER2-positive metastatic breast cancer following two or more prior HER2-based regimens. The updated data were presented in a Spotlight Poster Discussion at the 2020 San Antonio Breast Cancer Symposium (SABCS).

read corporate press release

Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS

(Puma) Dec 9, 2020 - Puma Biotechnology, Inc., a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial were presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation entitled, “Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial,” is being presented at a Spotlight Poster Discussion Session by Frankie Ann Holmes, M.D., FACP, Texas Oncology Houston – US Oncology Research, an investigator of the trial. A copy of this poster presentation is available on the Puma website.

read corporate press release

Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with HER2 Expressing Metastatic Breast Cancer Presented at the 2020 San Antonio Breast Cancer Symposium

(Daiichi Sankyo) Dec 10, 2020 - Initial results demonstrate ENHERTU may be safely combined with nivolumab, an immune checkpoint inhibitor in patients with HER2 positive or HER2 low metastatic breast cancer. Additional immunotherapy combination trials underway with ENHERTU to determine optimal combination strategies in these settings.

read corporate press release

G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival at 2020 San Antonio Breast Cancer Symposium

(G1 Therapeutics) Dec 9, 2020 - G1 Therapeutics, Inc., a clinical-stage oncology company, today reported final data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC) showing that trilaciclib significantly improved overall survival (OS) for patients treated with trilaciclib in combination with a chemotherapy regimen of gemcitabine/carboplatin (GC) compared with GC alone. These data were presented in a Spotlight Poster Discussion Session at the 2020 San Antonio Breast Cancer Symposium (SABCS). Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.

read corporate press release

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020

(Puma) Dec 9, 2020 - Puma Biotechnology, Inc., a biopharmaceutical company, presented updated results from the ongoing Phase II SUMMIT trial of neratinib at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation entitled, “Latest findings from the breast cancer cohort in SUMMIT – a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer,” is being presented at a Spotlight Poster Discussion Session by Komal Jhaveri, M.D., FACP, Memorial Sloan Kettering Cancer Center, an investigator of the trial. A copy of this poster presentation is available on the Puma website.

read corporate press release
Next Page